ࡱ> '` Rbjbjrr.' P P P d LLL8L|DMd ,N,N(TNTNTNPPP˵͵͵͵͵͵͵$jhһBQP MTP@PMTMT TNTN0B[[[MT 8TNP TN˵[MT˵[[ө8 P STN N `mLXNDzX0^}YSP StPQ[~RS;PPPs[^PPPMTMTMTMTd d hd";d d h;d d d   Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limited(a joint stock company established in the People s Republic of China with limited liability)(Stock Code: 0719)CONTINUING CONNECTED TRANSACTIONSSummaryReference is made to the announcement of the Company dated 28 October 2010. Continuing connected transactions between the Company and L. PerrigoThe Board announces that on 30 October 2013, the Company and L. Perrigo entered into the Perrigo Agreement in relation to the Company and/or its subsidiaries supplying pharmaceutical products to L. Perrigo and/or its affiliates for a period of three years from 1 January 2014 to 31 December 2016, unless terminated on six months written notice. As at the date of this announcement, L. Perrigo is a subsidiary of Perrigo Company. Perrigo Company is a connected person of the Company as it is the parent company of Perrigo International, which is a substantial shareholder of Xinhua Perrigo, a 50.1% owned subsidiary of the Company. Accordingly, L. Perrigo, being a subsidiary of Perrigo Company, is also a connected person of the Company and the transactions contemplated under the Perrigo Agreement will constitute continuing connected transactions under Chapter 14A of the Listing Rules.In respect of the proposed annual caps under the Perrigo Agreement for the three years ending 31 December 2016, as one or more of the applicable percentage ratios (as defined in the Listing Rules) exceed 5% and the annual consideration exceeds HK$10,000,000, the continuing connected transactions contemplated under the Perrigo Agreement constitute non-exempt continuing connected transactions and are subject to the reporting and announcement requirements under rules 14A.45 to 14A.47 of the Listing Rules, the independent shareholders approval requirement under rule 14A.48 of the Listing Rules, the annual review requirement under rules 14A.37 to 14A.40 of the Listing Rules and the requirements set out in rules 14A.35(1) and 14A.35(2) of the Listing Rules. Independent Shareholders approvalThe EGM will be convened and held to seek approval from the Independent Shareholders in relation to the continuing connected transactions and the proposed annual caps under the Perrigo Agreement. An Independent Board Committee has been established to advise the Independent Shareholders on the terms of and the proposed annual caps under the Perrigo Agreement.The Company has appointed Veda Capital Limited as its independent financial adviser to advise the Independent Board Committee and the Independent Shareholders on the terms of and the proposed annual caps for the Perrigo Agreement. A circular containing, among other things, (i) details of the Perrigo Agreement and the proposed annual caps; (ii) a letter from the Independent Board Committee to the Independent Shareholders; and (iii) recommendations of the independent financial adviser will be dispatched to the Shareholders on or before 20 November 2013. Background InformationThe Company entered into an agreement with L. Perrigo on 28 October 2010 in relation to the Company supplying the pharmaceutical products to L. Perrigo and/or its affiliates for a period of two years from 1 January 2011 to 31 December 2012, which was automatically renewed for a term of one year. An announcement was made on 28 October 2010.As the above agreement will expire on 31 December 2013, in order to secure the orders from L. Perrigo and/or its affiliates in the future, the Company has entered into the Perrigo Agreement with L. Perrigo for a period of three years commencing from 1 January 2014, unless terminated on six months written notice.Continuing connected transactions between the Company and L. PerrigoPerrigo AgreementDate : 30 October 2013Parties : (i) the Company (ii) L. PerrigoPrincipal terms and conditionsOn 30 October 2013, the Company and L. Perrigo entered into the Perrigo Agreement in relation to the Company and/or its subsidiaries supplying the pharmaceutical products to L. Perrigo and/or its affiliates, including Perrigo Company.The term of the Perrigo Agreement runs from 1 January 2014 to 31 December 2016 unless terminated on six months written notice.Payment termsThe price of the pharmaceutical products is based on market prices.L. Perrigo shall pay the Company within 60 days after invoicing. Proposed annual capsThe proposed annual caps for the continuing connected transactions under the Perrigo Agreement are as follows:-2014(RMB 000)2015(RMB 000)2016(RMB 000)Proposed annual caps48,00056,00065,000The Company has determined the above annual caps based on the following factors:-the historical figures in 2011, 2012 and January to September 2013 for the transactions between the Company and L. Perrigo and/or its affiliates (please see Table 1 below); the demand by L. Perrigo and/or its affiliates; the business development of the Company; andthe projected increase in the market prices of chemical raw materials for the production of the pharmaceutical products. Table 1- Historical figures in 2011, 2012 and January to September 2013 for the transactions between the Company and L. Perrigo and/or its affiliates2011 (RMB000)2012(RMB000)January to September 2013(RMB000)Total consideration45,96520,11327,561Reasons for and benefits of the continuing connected transactions between the Company and L. PerrigoBy selling the pharmaceutical products to L. Perrigo, the Company is able to expand its business in the United States. Accordingly, the Directors consider that the entering into the Perrigo Agreement is in the best interest of the Company and its Shareholders as a whole.The Directors also consider that the Perrigo Agreement has been negotiated on an arms length basis and the continuing connected transactions contemplated under the Perrigo Agreement are entered into in the ordinary and usual course of business on basis of normal commercial terms and that the terms of the continuing connected transactions under the Perrigo Agreement and the proposed annual caps thereof are fair and reasonable.As far as the Company is aware, no Director has a material interest in the transactions and therefore no Director is required to abstain from voting on the board resolution in relation to the transactions. Connected RelationshipAs at the date of this announcement, L. Perrigo is a subsidiary of Perrigo Company. Perrigo Company is a connected person of the Company as it is the parent company of Perrigo International, which is a substantial shareholder of Xinhua Perrigo, a 50.1% owned subsidiary of the Company. Accordingly, L. Perrigo, being a subsidiary of Perrigo Company, is also a connected person of the Company and the transactions contemplated under the Perrigo Agreement constitute continuing connected transactions under Chapter 14A of the Listing Rules.Implications under the Listing RulesIn respect of the proposed annual caps under the Perrigo Agreement for the three years ending 31 December 2016, as one or more of the applicable percentage ratios (as defined in the Listing Rules) exceed 5% and the annual consideration exceeds HK$10,000,000, the continuing connected transactions contemplated under the Perrigo Agreement constitute non-exempt continuing connected transactions and are subject to the reporting and announcement requirements under rules 14A.45 to 14A.47 of the Listing Rules, the independent shareholders approval requirement under rule 14A.48 of the Listing Rules, the annual review requirement under rules 14A.37 to 14A.40 of the Listing Rules and the requirements set out in rules 14A.35(1) and 14A.35(2) of the Listing Rules.Information about the Company and L. PerrigoThe Company is mainly engaged in the development, manufacture and sales of bulk pharmaceuticals, preparations and chemicals products.L. Perrigo is principally engaged in the manufacture, distribution and sale of certain over-the-counter, non-prescription pharmaceutical products in the United States. Independent Shareholders approval The EGM will be convened and held to seek approval from The Independent Shareholders in relation to the continuing connected transactions and the proposed annual caps under the Perrigo Agreement. An Independent Board Committee has been established to advise the Independent Shareholders on the terms of and the proposed annual caps under the Perrigo Agreement. The Company has appointed Veda Capital Limited as its independent financial adviser to advise the Independent Board Committee and the Independent Shareholders on the terms of and the proposed annual caps for the Perrigo Agreement. A circular containing, among other things, (i) details of the Perrigo Agreement and the proposed annual caps; (ii) a letter from the Independent Board Committee to the Independent Shareholders; and (iii) recommendations of the independent financial adviser will be dispatched to the Shareholders on or before 20 November 2013.DEFINITIONSIn this announcement, the following expressions have the meanings set out below unless the context requires otherwise:Boardmeans the board of Directors of the Company;Company means q\qge兡N gPlQS (Shandong Xinhua Pharmaceutical Company Limited), a joint stock company incorporated in the PRC with limited liability; Directors means the directors of the Company; EGM means the extraordinary general meeting of the Company to be held on 27 December 2013 for the purpose of approving the continuing connected transactions and the proposed annual caps under the Perrigo Agreement;Hong Kongmeans Hong Kong Special Administrative Region of the PRC;HK$means Hong Kong dollars, the lawful currency of Hong Kong;Independent Board Committeemeans the independent board committee of the Company comprising three independent non-executive Directors, which is constituted for the purpose of considering the Perrigo Agreement and the proposed annual caps thereunder; Independent ShareholdersShareholders who are not required to abstain from voting at the EGM;L. Perrigomeans L. Perrigo Company, a company established in the United States; Listing Rulesmeans the Rules Governing the Listing of Securities on the Stock Exchange;Perrigo Agreementmeans the written agreement entered into between the Company and L. Perrigo dated 30 October 2013;Perrigo Companymeans Perrigo Company, a company established in the United States;Perrigo Internationalmeans Perrigo International, Inc., a company established in the United States and a subsidiary of Perrigo Company;PRC means the Peoples Republic of China;RMB means Renminbi, the lawful currency of the PRC for the time being;Shareholdersmeans the shareholders of the Company; Stock Exchange means The Stock Exchange of Hong Kong Limited;Xinhua Perrigo7d e z { | }   x 4 Z \ м{smbUbhW5$CJOJPJQJo(hW5$KHnHo(tH hW5$CJhW5$CJPJhW5$CJPJo( hW5$6]hW5$CJo(hW5$nHo(tHhW5$6]o( hW5$o('jhW5$6U]mHnHo(tHuhW5$KHaJhW5$6KH]aJo(hW5$6KH]aJhW5$6KH]aJnHo(tH(jhW5$6KHU]aJmHnHu { } ~   x 2 4 Z \ ( $If$$7$8$H$Ifa$$If$$7$8$G$H$IfVDw^a$$G$H$a$G$H$$G$H$a$G$H$ $7$8$G$H$a$   # % ( ) I J n @Cch/Z]s  'YZ߹߹߱߹ߢ߹߹߹ߢߑߢߢߢߢߢߢ߱߱߇hW5$PJnHtHhW5$KHaJnHo(tHhW5$ hW5$o(hW5$PJnHtHhW5$nHtHhW5$PJnHo(tHhW5$5KH\nHtHhW5$5KH\nHo(tHhW5$nHo(tHhW5$>*OJQJo(hW5$>*OJPJQJo(5( ) n o  x $7$8$H$If$$1$7$8$H$Ifa$$7$7$8$H$If^7a$$7$7$8$G$H$If^7a$$$7$8$G$H$Ifa$$$7$8$H$Ifa$$$7$8$G$H$Ifa$ $$G$H$Ifa$Z,4-A ./auBemwMUb#$ź宦~hW5$KHPJhW5$KHo(hW5$KHPJnHtHhW5$KHPJnHo(tHhW5$KHPJhW5$KHPJnHtHhW5$5KHPJ\hW5$5PJ\h.hYPJnHo(tHh.hW5$PJhW5$PJnHo(tH hW5$PJhW5$PJnHtH/xyabf_G$[kd$$Ifq!!064 qa$$7$8$G$H$Ifa$$G$IfVD^$$7$8$G$H$Ifa$$$7$8$H$Ifa$  RSV$%&'FGXYcdοӶӶӶӶζζζӶΊ΁zhW5$PJo(hW5$KHaJo(hW5$hxPJnHo(tHhxnHo(tHhxhxnHo(tHhW5$nHtHhW5$nHo(tHhW5$CJOJPJQJaJo( hW5$o(hW5$PJnHo(tHh` 1hW5$KHPJh` 1h.o(h` 1hW5$KHPJnHtH/XY$77$8$G$H$^7a$$77$8$G$H$^7a$$77$8$G$H$^7a$ $7$8$G$H$a$$77$8$G$H$^7a$$7^7a$7^7 & F#77G$^7`dmyz)*mu=>QRrsܷέܦΞܖ܋ܦܷxhW5$PJaJo(hW5$PJnHtHhW5$PJnHo(tHhW5$nHtHhW5$5\o(hW5$KHo(hW5$5KH\o(hW5$KHnHtHhW5$KHPJnHo(tHhW5$5KH\nHo(tHhW5$KHnHo(tH hW5$PJhW5$PJo(hW5$PJnHo(tH+$77$8$G$H$^7a$$ & F nn7$8$G$H$^n`a$$77$8$^7 $7G$H$^7a$$77$8$G$H$^7a$$7$8$G$H$^a$$7$8$G$H$^a$12$$7$8$G$H$Ifa$$$7$8$G$H$Ifa$$87$8$G$H$^8a$$77$8$G$H$^7a$$7d^7` 1O{Tٸ٨vvvaZhW5$aJo()hlzhW5$5KHPJ\aJnHo(tHhW5$PJnHo(tH(hlzhW5$5PJ\mHnHo(tHu"hW5$5PJ\mHnHo(tHuhW5$5\mHnHo(tHuhW5$5\o(hW5$5\nHtHhW5$5PJ\nHo(tHhW5$5\nHo(tHhW5$nHtHhW5$nHo(tHhW5$OJQJo(k\MMM$$7$8$G$H$Ifa$$$7$8$G$H$Ifa$kd$$Ifq\l! TT5064qaSTk]TN3$ & F nn7$8$G$H$^n`a$8^8^gdlz$7$8$G$H$a$gdlzkdF$$Ifq\l! TT5064qaTnprvx}5Tabcgqz !#$%UVvxzڵ򩗌hW5$5KH\aJ#hW5$5KHPJ\aJnHo(tHhW5$5KH\aJo(hW5$KHaJnHtHhW5$KHPJnHo(tHhW5$KHPJnHtHhW5$KHPJaJnHo(tHhW5$KHaJo(hW5$KHaJnHo(tH145bctuvu^$T$7$8$G$H$If^a$$T7$8$G$H$^a$$77$8$G$H$^7a$$T7$8$G$H$a$$887$8$G$H$^8`a$$n7$8$G$H$a$$ & F nn7$8$G$H$^n`a$$887$8$G$H$^8`a$ vOkd$$Ifq4\ H! T 064 qa$T$7$8$G$H$Ifa$% & I J K L M µ臭yqyyqbhW5$KHPJaJnHo(tHhW5$KHaJhW5$KHaJnHo(tHhW5$KHaJo(h!yKHPJnHo(tHhW5$KHPJnHo(tHhW5$KHPJnHtHhW5$KHaJnHo(tHhW5$5KH\aJo(hW5$5KH\aJnHtH#hW5$5KHPJ\aJnHo(tHhW5$5KH\aJnHo(tH&$T$7$8$G$H$Ifa$$T$7$8$G$H$If^a$$T$7$8$G$H$If^a$J K dYJ5$7$8$G$H$VD^`a$$77$8$G$H$^7a$ $7$8$G$H$a$kd$$Ifq"\ H! T 064 qa ! !!Y!\!]!i!}!!!!" """ # #ʸʬʬʝʝ}o}aVaVaGhW5$KHPJaJnHo(tHhW5$KHnHo(tHhW5$KHmH nHsH tHh` 1hW5$KHnHo(tH h` 1hW5$KHmH nHsH tHh` 1hW5$KHaJnHtHh` 1hW5$KHaJnHtHh` 1hW5$KHaJo(#h` 1hW5$KHPJaJnHo(tHh` 1hW5$KHaJnHo(tHh` 1hW5$KHaJnHo(tHh` 1hW5$KHaJo(hW5$KHaJo(K [!\! # #####&&6&7&2)3)`)a))) 7$8$H$VD^$77$8$H$^7a$$7d^7`$77$8$G$H$^7a$$7$8$G$H$a$gdx;$77$8$G$H$^7a$ # #b#c#######$F$I$Y$$$$$$3%>%J%Q%%%%%&&6&7&&&&''9'>'w'''((1(x((((µ¬š􊐊h.hW5$PJ hW5$PJhW5$PJnHtHhW5$OJQJo(hW5$ hW5$o(hW5$nHo(tHhW5$KHaJnHo(tHhW5$nHtHhW5$5\o(hW5$B*PJaJnHphtH"hW5$B*PJaJnHo(phtHhW5$PJnHo(tH/()0)1)2)3)T)_)`)a))))))))))q*y*****@.ǻwj^jRKRChW5$KHaJ hW5$5\hW5$KHPJnHtHhW5$KHaJnHtHhW5$KHaJnHo(tHhW5$CJKHOJPJaJo(hW5$KHPJaJo(hW5$KHPJaJnHo(tHhW5$KHPJaJhW5$KHaJo(hW5$5\o(hW5$5KH\aJo(hW5$KHPJaJnHo(tHhW5$PJnHo(tHhW5$PJnHtH hW5$PJh.h'PJnHo(tH)***|+~+$,%,--W.X.d.e..... $7$8$G$H$If7$8$G$H$ & F#77G$^7`$77$8$H$^7a$$U7$8$G$H$^`Ua$ $7$8$G$H$a$$77$8$G$H$^7a$@.E.Q.W.X.c.d.e.......///$0F0H0001101<1v1~1 222(222222222$3(3(4)4;h'KHPJnHo(tHh` 1h.KHPJnHo(tHh` 1hW5$KHhW5$KHo( hW5$KHhW5$5KH\aJo(hW5$CJOJPJQJaJo(hW5$CJOJPJQJaJhW5$KHPJnHtHh` 1h.PJnHo(tHh` 1hW5$KHaJ+.///11121z1LLkd#$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$z1|1~1111222LLkd$$If0 ! 64 a8 $7$8$G$H$IfLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$222222&3'3(3LLkd$$If0 ! 64 a8Lkds$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$If(3<3G3}333)4*4+4D444LkdS$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$If )4*4+4C444444444444441525:5>5?5P5Q555555555566%6s6666666666777#7$7&7N7O7`7f7777778ŸŸŨŦUhW5$B*KHnHo(phtHhW5$KHPJnHo(tHhW5$KHnHo(tHhW5$KHnHtH hW5$KHhW5$KHaJhW5$KHo(h'h'KHPJnHo(tH>4444444<5=5LLkd3$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkd$$If0 ! 64 a8=5>5R55555 66LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkd$$If0 ! 64 a866&6666666LLkd$$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkd$$If0 ! 64 a8666777%7&7N7LLkd $$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkdc $$If0 ! 64 a8N7O7a77777>@LLkd $$If0 ! 64 a8$$7$8$G$H$Ifa$ $7$8$G$H$IfLkdC $$If0 ! 64 a8meansmZSe-~v)Rؚ gPNlQS(Zibo Xinhua-Perrigo Pharmaceutical Company Limited), a PRC joint venture owned 50.1% by the Company and 49.9% by Perrigo International. By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman30 October 2013, Zibo, PRCAs at the date of this announcement, the Board comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Du DepingMr. Zhao SongguoIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Bai HuiliangMr. Kwong Chi Kit, VictorNon-executive Directors: Mr. Ren FulongMr. Xu LieMr. Zhao BinPAGE 1PAGE 78>@BFHtƒ҃ 68:<ʅNPlnˈwmwmwmwiwa]hPjhPUhW5$hW5$PJnHtHhW5$nHtHhW5$nHo(tH hW5$o(hW5$6KH]aJhW5$6KH]aJo(hW5$5KH\aJnHo(tHhW5$5KH\aJo(hW5$5KH\aJhW5$KHaJhW5$KHPJaJnHo(tHhW5$KHo(hW5$KHaJo(hW5$KHaJnHo(tH$@BDFHt҃8s`$, 7$8$G$H$^ a$$< 7$8$G$H$^ a$$ 7$8$G$H$^ a$ $7$8$G$H$a$$7$8$G$H$^`a$Lkd# $$If0 ! 64 a8 8:<ބ4VX…PnGkd $$If0!64 a $$G$Ifa$$G$a$Ԇֆ؆$4$a$&`#$Gkd $$If0!64 a $$G$Ifa$̆ΆІ҆Ԇ؆چԽ hW5$o(hW5$CJo(h` 10JmHnHuhW5$hW5$0JmHnHu hW5$0JjhW5$0JUhPjhPU/0P/ =!"#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCB*KHPJaJnHtH$A@$ ؞k=W[SOFi@F nfh*KHOJ PJQJ nHtHhS@h ckee,g)ۏ 3$$7$8$G$H$^a$KHPJWDFnHtH.. yblFhe,gCJaJpOpChar Char Char Chard1$CJKHPJaJmHnHtHu._. {}~-.PQRZ[JKklh i R S *+,-.EF12IJdewxXY"#$)49DITUjqx]^ .89MTU\cde((.0000000 00000000000000000000000000000000J0J# 00!0!0!0!0!J# 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 j0 06 0606 0606:000000000000 0 0 0 0 0 000 00 00 00 00000 000000 0 00 0004 000000ʑ0}0~P 000ʑ00T ) {}~-.PQRZ[JKklh i R S *+,-.EF12IJdewxXY"#$)49DITUjqx]^ .89MTU\cde[\stg h !!7!!!""##$$$$\%]%e%f%%%%*&+&,&8&\&]&^&e&f&&:';'<'H''''''''''(S((((((()))*)7)~))))))))T*U*V*h*****8+9+:+A+g+h+i+p++++++++,/,0,1,B,,,,,,,,+-9-B-C-^-_-`--------.#.4.N.O.P.j.y.........................08000000000000000000000000000000000000 0 H0H# 00.0.0.0.0.H# 0000000000000000h00 00 00800000 00 00 00 0 0 0 0 0 0 000 00 00 00 00000 0 00 00 0 0 00 0 0 0 000000000008000000800g 0g 0g 0g 0g 0g 0g 0g 0g 0g 0g H# 0g 00000 0 0 0 00 0 0 00 0 00 000 0 0 00 0 0 00 0 00 00000 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 0 00 0 00 0 0 0 00 0 0 00 0 000000000000000000 00000 0 00000 0 0 0@0ȑ00)@0ȑ00)@0ȑ00)@0ȑ00)@0@0@0@0@0@0ȑ00)00 {}~-.PQRZ[JKklh i R S *+,-.EF49DITUx89MTU\cdeg h !!7!!!""##$%%+&,&\&]&^&e&f&&:';'<''''''''(S(((((()))*)))))U*V***9+:+h+i+++++0,1,,,O.P....0000000 00000000000000000000000000000000J0J# 0ʑ00ʑ00ʑ0+0?,ʑ0+0>ʑ0+0<ʑ00ʑ009ʑ00ʑ0-08.ĭʑ00ʑ000000ʑ00ʑ00ʑ0:01ʑ00ʑ0<01ʑ00ʑ00 4ʑ00ʑ0@05Aدʑ00ʑ00ʑ00"*0**0ʑ00ʑ0L0-M ʑ0L0,ʑ0L0*1ʑ00ʑ00ʑ00ʑ00ʑ00ʑ00ʑ00ʑ00ʑ00L1 # ʑ000 ʑ0\0'] ʑ00!0 ʑ00ʑ00ʑ00ʑ00ʑ00N ʑ000! ʑ0g0!hʑ000 ʑ00ʑ00ʑ00ʑ00ʑ00ʑ000D ʑ00ʑ00ʑ00 ʑ00 ȱ0 ʑ0!0" N2! ʑ0#0$X0 ʑ0%0&v ʑ0'0(0 ʑ0)0*(!0 ʑ0+0,`4 ʑ0-0."&3pF ʑ0/003#0 ʑ010230 ʑ03044x2& ʑ0506H40 ʑ00) &&&) ZdT #(@.)4!#%(+.1346;DH( xvK ).z12(34=566N7@8 "$&')*,-/025789:<=>?@EFGI  ")!4!t  ,b$l?xK-}*1@Z (  \ _ 3 _"?\  S A"?B S  ?H0(  {._|!LtxPtSmTySm|wSmySm4ySmySmySmdySmySmySm6wSmt7wSm 8wSm9wSm9wSmd:wSm;wSm;wSmsw33!!=''n)n)**++`+`+T-T-.    @@!!F''{){)**++e+e+X-X-. B*urn:schemas-microsoft-com:office:smarttagscountry-region8*urn:schemas-microsoft-com:office:smarttagsCity9*urn:schemas-microsoft-com:office:smarttagsplace /6HOsz7>y> E   ' t{IPcj&ovIPry\cGN;B$ah)0k r !!""y######%%''.'((.)5)@)G)))5*<*W*^*n*u*****'+.+v+~+9,@,G,K,L,W,d,k,,,1-8-------.".'.*.+.3.8.=.n.q.r.x.}.................%)&B,,...............33  3 9 #==OOmmnHH((MMSSUU[[\b\\EE~!7!$$^&e&&&''((*)7)................................$>k/0h{c  u:%M bU^X.` KP $Y[T^T3j s/?!c0 $%̛P& Q.'FFk4C41e$M8NyeW:Xi9AT~ZATΈdDNtT\I\FGKLjE|Lb7Q 'C U8CYR-J^sB`6sRdzke$M8 TiT3j Y[{c 7Q:%M E|Lmw-J^//?!ukxQ.'sRdi9A\IwoB`yeW:P& $%dDZAKP vW~GK$$%        Zn       r        f#h        ’                         x0>b*       oTԚ=      Gi                          f:Ob|       &"N                 :        g0       H{*       U        b        ,:        J         Lr        f6                          X"        tX        H                 Jmwld      6N        }`        *        ܞ        4        'YW5$[(` 1FKn!y.j';x;?lzAYnNxP,>`PQ,-"#$4DTUjqx^89MU\cd\$\%]%f%%%%+&,&8&]&^&f&;'<'H'''''''((())*)7)))))))U*V*h****9+:+A+h+i+p++++++,0,1,B,,,---O.P.....Y@&&&&L%&B,.@@@ @@@0@d@@Unknown Gz Times New Roman5Symbol3& z ArialC .PMingLiUe0}fԚ;[SOSimSunKM  DFKai-SBPMingLiUOTimesLTStd-Roman[SO] Times-BoldTimes New RomanQ MSung-LightPMingLiU_ Times-RomanTimes New Roman 1hG'!'T'T!?!),.:;?]}    " % & ' 2 t%00 0 000000013468:<>@BDOPQRTUVWZ\^ \]d([{  5 0 0 00000579;=?ACY[][d~.~. 2qHX ?,2~The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation CHRYSEISYUiegm$                           ! " # Oh+'0(4HT`p    The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation CHRYSEISYUNormaliegm15Microsoft Office Word@,@ @.(K@2m'՜.+,0 X`t|  CharltonsT~.'   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_abcdefgijklmnopqrstuvwxyz{|}~Root Entry F`UmData `1TablehWordDocumentSummaryInformation(DocumentSummaryInformation8CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q